REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/02/2026
Back to search
Official data from USPTO
CELULARITY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CELULARITY
ST13
US500000090002793Class
1, 5
Filing
90002793
Registration
6260135
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
02/03/2026
Trademark type
Word
Nice classes
1, 5
Filing date
06/15/2020
Registration date
02/02/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/02/2021
Last transaction
02/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
12/06/2018
First use in commerce
12/06/2018
Drawing code
4
Owner type
11
Owner location
SINGAPORE, SG
Examiner
LINERO GUARDA, GERARDO INAKI
Law office
N90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
CELENIV PTE. LTD.
CELULARITY INC.
Celularity, Inc.
Representatives
Camille M. Miller COZEN O'CONNOR
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
bioengineered cells for use in scientificlaboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientificlaboratory and medical research
Class 5
Cells and biological preparations intended for medical and clinical usebloodstem cellsumbilical cord cellsumbilical cord bloodplacental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical useplacental-derived natural killer cellsplacental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen;biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical useplacental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen
Publications
History of USPTO decisions and trademark events.
20 publications found
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/07/2026
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
02/02/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/17/2020
PUBO
PUBLISHED FOR OPPOSITION
11/17/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/28/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/09/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/08/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/08/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/16/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/15/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/15/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/07/2020
GNRT
NON-FINAL ACTION E-MAILED
08/07/2020
CNRT
NON-FINAL ACTION WRITTEN
08/07/2020
DOCK
ASSIGNED TO EXAMINER
08/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/14/2020
NWAP
NEW APPLICATION ENTERED
06/18/2020
Continuous trademark protection
Get notified about every new filing that threatens CELULARITY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.